Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sunshine Biopharma Inc. - Warrant (NQ: SBFMW ) 0.0800 +0.0100 (+14.29%) Streaming Delayed Price Updated: 12:42 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sunshine Biopharma Inc. - Warrant Sunshine Biopharma Q2 Report Reveals Approximately 1,940% Increase In Cash & Cash Equivalents And 80% Decrease In Net Loss Within 6 Months August 08, 2022 Sunshine Biopharma, Inc. (NASDAQ: SBFM) (NASDAQ: SBFMW) announced that it has filed its 2022 second-quarter report with the Securities and Exchange Commission. Via Benzinga Sunshine Biopharma Reveals Potential Intellectual Property Position In Connection With Ongoing mRNA-As-Therapeutics-Agents Research April 26, 2022 Photo credit: Patent application by Nick Youngson CC BY-SA 3.0 Via Benzinga Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells April 25, 2022 Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc. Via Benzinga Sunshine Biopharma Sees Potential Multi-Billion Dollar Global Market Opportunity As Research Findings Reveal Effectiveness Against Multidrug-Resistant Cancer Cells April 06, 2022 Photo by Angiola Harry on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga Sunshine Biopharma, Inc. Announces Pricing of $8 Million Private Placement Priced At-the-Market March 14, 2022 Photo by Scott Graham on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... Via Benzinga Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW) February 17, 2022 NEW YORK, NY / ACCESSWIRE / February 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ:SBFM; SBFMW)... From Aegis Capital Corp. Via AccessWire Exposures COVID-19 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.